◆英語タイトル:Brazilian Pharmaceutical Market Outlook 2016-2026
Sigle User(1名利用)GBP1,999 ⇒換算¥267,866見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥401,866見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥669,866見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。


1. レポート概要

2. ブラジル医薬品市場の概要

3. ブラジル市場の重要性

4. ブラジル医薬品市場の構成

5. ヘルスケアに関する地域間の主要な違い

6. ブラジル医薬品市場における製品区分2016-2026

7. ブラジル市場における治療領域2015-2026

8. ブラジル市場における国内企業

9. ブラジル市場における多国籍企業

10. ブラジル医薬品市場の定性分析2016

11. 調査インタビュー

12. 調査・分析の結論

Medicine Sales in Brazil – How to Find Trends, Opportunities and Forecasted Revenues
Do you want to assess Brazil’s pharmaceutical market from 2016? If so, visiongain’s new report gives you revenue forecasts, helping your research and analysis. That study’s purpose is to show opportunities, trends and sales predictions to 2026.

Brazil can satisfy expectations for wider healthcare coverage and rapid expansion of its pharma industry and market. With our updated study you explore business analysis, developments and opportunities for domestic and foreign companies.

Please read on to explore Brazilian medical sales and see how high that fast developing country’s revenues could go.

Trends and outlooks for that emerging healthcare market – what is possible?
From 2016 patients, treatment providers and the pharmaceutical industry will benefit from progress in Brazilian healthcare. Discover in our study what the future holds – medical needs and potential revenues. Also find rankings of companies.

Our new analysis shows you revenue predictions from 2016 to 2026 at overall national and submarket levels. You discover the most lucrative parts of that country’s drug market, seeing opportunities to benefit patients, healthcare providers and pharma companies. Explore what the future holds for domestic producers and multinational pharma companies.

Forecasts and other data help you find where the money lies in Brazil’s medical sales
To support our forecasting, our work shows you historical results, sales growth rates and market shares. In our 191 page report you gain 52 tables, 55 charts and interviews with representatives from BiocadBrazil Farmaceutica and Sandoz Brazil.

With our study, see how you could save time and avoid struggles to find data to help your research, analysis, plans and presentations. See, too, how you could help your influence, benefiting your reputation for commercial insight on Brazilian pharma.

The following sections show how our investigation helps your work.

Potential of Brazil’s drug sales – overall market and segment forecasts
What is Brazil’s potential as a pharma market? In our analysis you discover overall revenues to 2026, with discussions. Our report also shows you individual sales predictions – from 2016 to 2026 – for three main submarkets:
• Patented therapies – original brands of prescription drugs
• Generic pharmaceuticals (generics)
• OTC medicines – over-the-counter treatments.

The future looks promising for Brazilian pharmaceutical sales. That developing national market is growing at a faster rate than more-mature markets, and can continue to do so over the next ten years. See what is possible.

With our study also extend your knowledge of that country’s medical needs and pharma industry. In addition you explore forecasting for therapeutic applications, assessing demand and potential revenues.

Diseases and their treatment – what prospects for drugs and their sellers?
Our new study also predicts revenues in Brazil for treating prominent diseases. See individual revenue forecasts to 2026 for six therapeutic categories:
• Central nervous system (CNS)
• Cardiovascular (CV)
• Gastrointestinal and metabolic
• Cancer treatments (oncology)
• Infectious diseases – anti-infective agents (vaccines and antibiotics)
• Therapies for other disorders (grouped analysis).

How fast will those submarkets expand? How high will their revenues go? With our report you assess opportunities and potentials, seeing what developments and sales are possible.

There you also investigate what stimulates and restrains sales of drugs.

Issues and events in Brazil – what affects drug developers, producers and sellers?
Our study discusses forces affecting Brazil’s medical sales from 2016, including these influences:
• Efforts of companies and public healthcare providers to serve patients’ needs
• Strategies of domestic and foreign companies, including mergers and acquisitions (M&A), drug launches, sales ranking and Brazilian market share
• Trends in demographics, economics and epidemiology – assess medical needs, including Zika virus infection
• Wholesalers, distributors and retailers of medicines – the supply chain
• Governmental policies – explore activities of ANVISA and SUS and other bodies – including the new drug price adjustment system, the RENAME reimbursement programme and ANVISA reform of patent protection.

With our study you also assess these influences, among others:
• Efforts by regions to improve medical provision, better serving populations
• Healthcare insurance – public and private – to improve access to medicines
• Technologies – competitors’ research and development and manufacturing
• Technology transfer and IP protection, including action against counterfeiting
• Rising demand for biological drugs, including biosimilars
• Brazil’s position in overall world, Latin American, BRIC nations and pharmerging countries’ pharmaceutical markets.

With our analysis you examine political, economic, social and technological questions, assessing commercial prospects. You also investigate strengths, weaknesses, opportunities and threats.

Explore what stimulates and restrains domestic and foreign pharmaceutical companies in Brazil, discovering what is possible from 2016 to 2026.

Analysis of top companies and their industry – what future sales are possible?
What happens next? Our work predicts the Brazilian pharma market will reach $31.1bn in 2020 – with strong expansion from 2016 to 2026. See what is possible.

In our report you discover what causes that sales growth and why Brazil attracts and develops pharma business. There you explore activities of 10 leading domestic companies and other firms, including these organisations:
• Hypermarcas
• Aché
• Eurofarma
• Cristália
• Libbs
• União Química.

You also assess 10 multinational – big pharma – organisations and other foreign players operating there, including these corporations:
• Sanofi
• Novartis
• Roche
• Pfizer
• Takeda
• Bayer
• Merck & Co.

You also see interviews with BiocadBrazil Farmaceutica and Sandoz Brazil. Discover the efforts of pharma specialists, including firms making biopharmaceuticals. From 2016 many firms stand to gain.

Leading generic and biosimilar drug developers, producers and sellers
In our report you assess other international manufacturers and marketers of drugs for Brazil, including generics and biosimilars:
• Teva Pharmaceutical Industries
• Mylan
• Actavis
• Daiichi Sankyo
• Glenmark
• Valeant
• Strides Arcolab
• Biocon.

Pharma industry leaders and specialty companies will expand their operations and sales there. Explore what is possible in Brazil and see how you could benefit.

5 ways Brazilian Pharmaceutical Market Outlook 2016-2026 helps your work
In these five main ways, our investigation gives knowledge to benefit your research, analyses and decisions:
• Brazil’s overall pharma revenues from 2016 – discover that leading developing country’s prospects for medical investments, marketing and sales
• Submarkets’ revenues to 2026 – investigate 9 segments at national level, finding product groups and therapeutic needs with highest potential revenues
• Prospects for domestic and foreign drug developers, producers and sellers – explore portfolios, R&D, product approvals, collaborations, M&A and outlooks
• Opinion and news from companies – see views to help you stay ahead in knowledge, including two interviews
• Analysis of what stimulates and restrains Brazil’s market for human medicines – assess challenges and strengths there, helping you compete and gain advantages.

That study, by our in-house analysts in the UK, gives data to benefit your work. Our survey shows information you find nowhere else, helping you stay ahead.

Independent analysis showing you the potential of Brazil’s pharma sales
Our report gives analysis showing you the most promising opportunities. Discover progress and possibilities for pharmaceutical sales in Brazil.

Through choosing our study, see how you could save time and effort, also benefiting your authority and reputation for commercial insight.

Our investigation is for everyone analysing rising and emerging pharma markets. Brazil holds great commercial potential – our study shows you trends, forecasts and discussions to help you stay ahead in knowledge. So avoid missing out – please get our new report here now.


1. Report Overview
1.1 Brazil: Pharmaceutical Market Overview
1.2 Brazilian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Survey
1.6 Who is Our Report For?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQs)
1.9 Some Associated Reports
1.10 About Visiongain

2. Introduction to the Brazilian Pharmaceutical Market
2.1 The Brazilian Pharmaceutical Market Overview
2.2 Generics Segment Continues to Grow in Importance
2.3 CNS – The Largest Therapeutic Area in 2015
2.4 Four Domestic Companies in the Top Ten in 2015

3. The Significance of the Brazilian Market
3.1 Brazilian Economy is the Ninth Largest in the World
3.2 Brazil is the Eighth Largest Pharmaceutical Market
3.3 Brazil is the Largest Market in Latin America
3.4 Brazil Qualifies as a ‘Pharmerging’ Country and one of the BRIC Markets

4. Organisation of the Brazilian Pharmaceutical Market
4.1 ANVISA – Brazil’s Equivalent of the FDA
4.2 Other Influential Organisations
4.3 SUS – One of the World’s Largest Public Health Systems
4.4 Private Healthcare Accessed by 25% of the Population
4.5 Private Insurance Market Growing but Costs are Rising
4.6 New Drug Price Adjustment System Introduced
4.7 RENAME Drug Reimbursement System and the Farmácia Popular
4.8 Extensive Network of Pharmacies in Brazil
4.9 Wholesale and Retail Sectors Undergoing Consolidation
4.10 Panpharma is the Top Wholesale Distributor
4.11 Profarma is the Largest Mixed Distributor
4.12 Raia Drogasil is the Leader in the Retail Sector
4.13 Spending on Marketing Approaches $5bn

5. Major Differences in Healthcare Between Regions
5.1 Size and Prosperity of Different Regions
5.2 South-East is the Richest and Most Populous Region
5.3 South Has the Second Highest GDP
5.4 North-East Has the Second Highest Pharmaceutical Market Share
5.5 North is the Largest and Poorest Region
5.6 Mid-West is a Landlocked Region Housing the Nation’s Capital

6. Product Segments in the Brazilian Pharmaceutical Market 2016-2026
6.1 Forecasts for the Originator, Generic and OTC Segments 2015-2026
6.2 Originator Segment Will be Overtaken by Generics
6.2.1 Product Development Partnerships to Reduce Costs
6.2.2 Originator Drugs Threatened by 35% Cheaper Generics
6.3 Generics Drug Segment Forecast 2015-2026 – Continued Rapid Growth
6.3.1 Rapid Expansion of Generic Segment
6.3.2 Generic Companies Aiming for 45% Market Share
6.3.3 Similares Drugs Face Same Pricing Rules as Generics
6.3.4 Counterfeit Drugs Account for 20% of the Market
6.3.5 National Drug Security System to Tackle Counterfeit Drugs
6.3.6 Challenges for the Brazilian Generics Market
6.4 Brazilian Biologics Market
6.4.1 Biosimilars Market to Double in Size by 2017
6.4.2 BiocadBrazil Brings More Biosimilars to Brazil
6.5 OTC Drug Segment Forecast 2015-2026
6.5.1 Analgesics and Multivitamins Favoured by Brazilians
6.5.2 One Sixth of Population Buy Multivitamins
6.5.3 Restrictions on OTC Products Reversed
6.5.4 Consumer Health Treatments Remain Prominent in the Market

7. Therapeutic Areas of the Brazilian Market 2015-2026
7.1 Forecasts for CNS, Cardiovascular, Gastrointestinal/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2016
7.2 The Rise of Non-Communicable Diseases
7.3 Market Forecast for CNS Conditions 2015-2026
7.3.1 CNS Conditions Currently the Largest Therapeutic Area
7.3.2 Domestic Companies Target Generic and OTC CNS Products
7.3.3 Foreign Companies Target Analgesics Market
7.3.4 One Fifth of Brazilians Have Suffered Depression
7.3.5 CNS Conditions: Drivers and Restraints
7.4 Market Forecast for Cardiovascular Therapeutic Area, 2015-2026
7.4.1 Rate of Cardiovascular Disease Expected to Triple
7.4.2 Almost One Quarter of the Population are Hypertensive
7.4.3 Statin Revenues Decline with Loss of Patent Protection
7.4.4 Domestic and International Companies Compete in CVS
7.4.5 Cardiovascular Opportunities and Challenges
7.5 Market Forecast for Gastrointestinal/Metabolic Therapeutic Area, 2015-2026
7.5.1 High Prevalence of Diabetes and GI Conditions
7.5.2 Low Awareness of Diabetes Amongst Population
7.5.3 Drive for Domestic Production of Insulin
7.5.4 EMS’s Generic Esomeprazole an Important Addition
7.5.5 Capturing the Gastrointestinal/Metabolic Disease Opportunity
7.6 Market Forecast for Oncology Therapeutic Area, 2015-2026
7.6.1 Cancer Treatment to Become the Leading Therapeutic Area
7.6.2 Increased Coverage of Cancer Care by Private Health Insurance Providers
7.6.3 What are the Commonest Cancers in Brazil?
7.6.4 Biosimilars Will Help Widen Access to Cancer Drugs
7.6.5 Cristália and Libbs Amongst Leading Oncology Companies
7.6.6 Promising Potential of the Oncology Therapeutic Area
7.7 Market Forecast for Infectious Diseases Therapeutic Area, 2015-2026
7.7.1 Vaccines and Antibiotics Lead Therapeutic Area
7.7.2 Brazil Increasingly Manufacturing its Own Vaccines
7.7.3 First Vaccination Programme Against Dengue Fever
7.7.4 Free Access to HIV Care Despite Concerns About Patent Protection
7.7.5 Chagas Disease and Other Tropical Infections
7.7.6 Long-Term Threat From Zika Virus Epidemic
7.7.7 Importance of Infectious Diseases Compared to Chronic Diseases
7.8 Market Forecast for Other Therapeutic Areas, 2015-2026

8. Domestic Companies in the Brazilian Market
8.1 The Top Ten Domestic Pharmaceutical Companies in 2015
8.2 Multinational Companies Still Own the Majority of the Market
8.3 Domestic Sector Actively Encouraged by Government
8.4 Domestic Firms Control 70% of Generics Market
8.5 EMS: Brazil’s Leading Pharmaceutical Company
8.5.1 Separate Divisions for Different Drug Categories
8.5.2 Full Production and R&D Capability
8.5.3 Legrand and Germed are Key Subsidiaries
8.5.4 Targeted Expansion Overseas
8.6 Hypermarcas: Market Leader in OTC and Branded Generics
8.6.1 Neo Quimica: Ranked Third in the Generics Segment
8.6.2 Subsidiaries Include Mantecorp and Brainfarma
8.7 Medley: Generics Company Owned by Sanofi
8.8 Aché: A Major Acquisition Target in Brazil
8.8.1 Anti-Inflammatory Acheflan Was First Drug Developed in Brazil
8.8.2 Involvement of Aché in Acquisitions Process
8.8.3 Part of Bionovis Collaboration
8.9 Eurofarma: Fifth Largest Domestic Company with Plans to Cover 90% of Latin America
8.9.1 Policy to Make Acquisitions in Latin America
8.10 Teuto Operates Largest Pharmaceutical Complex in Latin America
8.10.1 Melcon Partnership and Other Growth Strategies for Teuto
8.11 Biolab Farmaceutica Leads Cardiology Drugs Market
8.11.1 Partnering With German and Indian Companies
8.11.2 Current Pipeline and Product Launches
8.12 Cristalia: Largest Producer of Anaesthetics in Latin America
8.12.1 Approval from ANVISA to Produce Biosimilar Drugs
8.12.2 Leader in API Manufacturing
8.12.3 Involved in One Third of all PDPs
8.13 Libbs: Key Player in Cancer Treatment
8.13.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
8.14 União Quimica: Huge Annual Production Capacity
8.14.1 Agreement with Novartis and Possible Public Offering in 2015
8.15 Other Domestic Players Include Laboratório Daudt Oliveira and Hebron
8.16 Biosimilar Collaborations
8.16.1 Bionovis: Conglomerate Developing 8 Biosimilars
8.16.2 Orygen: Conglomerate Aiming to Develop 7 Biologics
8.16.3 Other Biotech Players Include Biomm and Innova
8.16.4 Fiocruz: At the Heart of Multiple PDPs
8.16.5 ANVISA Reform of Brazilian Patent System

9. Multinational Companies in the Brazilian Market
9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2015
9.2 Notable M&A Activity
9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
9.3.1 Group Companies Include Sanofi Pasteur and Genzyme
9.3.2 Inventory Mishandling and Dip in 2013 Results
9.4 Novartis: Only Multinational to Produce APIs in Brazil
9.4.1 PDPs and a New $342m Biotechnology Facility in the North East
9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
9.4.3 Investment in Expansion Plans
9.5 Roche: No Regrets About Staying in Brazil
9.5.1 Oncology Opportunity and Herceptin Pricing
9.6 Merck & Co. – Long-Standing Presence in the Brazilian Market
9.6.1 Five Factories and Five Broad Therapeutic Areas
9.6.2 Gardasil Added to SUS in 2013
9.6.3 Joint Venture with Eurofarma and Cristalia
9.7 Pfizer: Pursuing Strategy to Acquire Domestic Manufacturers
9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
9.8 Takeda: Expanding its Brazilian Business
9.8.1 Acquisitions of Nycomed and Multilab
9.9 Bayer: Brazil is its Fifth Largest Market
9.9.1 OTC is a Major Focus in Brazil
9.10 AstraZeneca Targets Latin America
9.10.1 Struggling with Loss of Exclusivity and Patent Infringement
9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
9.11.1 Looking to Acquire OTC Brands
9.11.2 Technology Transfer Deal for Parkinson’s Disease
9.12 Merck KGaA Signed PDP with Bionovis for 8 Biosimilars
9.12.1 Two Divisions and Multiple Therapeutic Fields
9.13 Other Notable Multinationals in Brazil
9.13.1 GSK: Vaccines and Technology Transfer Opportunities
9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil?
9.13.3 Abbott: Generics and Diagnostics-Led Growth Strategy
9.13.4 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
9.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
9.13.6 Baxter Entering Haemophilia Market Via Technology Transfer
9.13.7 Johnson & Johnson: Focusing on Consumer Health and Commodities
9.13.8 BiocadBrazil Farmaceutica
9.13.9 Amgen Signals Brazilian Intent with Bergamo Acquisition
9.13.10 Gilead, Novo Nordisk, Biogen, UCB and Meizler
9.13.11 Other Top Japanese Companies Trail Behind Takeda in Brazil
9.14 Will Multinational Generics Leaders Compete in Brazil?
9.14.1 Teva Targets Brazil
9.14.2 Mylan Acquires Agila to Boost Brazilian Strategy
9.14.3 Actavis May Target Brazil
9.14.4 Ranbaxy and Daiichi Sankyo
9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
9.14.6 Valeant: M&A Drive Into the Market
9.15 Brazil as a Pharmaceutical Research Destination

10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2016
10.1 Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis
10.1.1 A Crucial Market for the Pharmaceutical Industry
10.1.2 Government Regulation Remains an Issue
10.1.3 One of the Highest Pharmaceutical Tax Rates in the World
10.1.4 Room to Expand in Therapeutic Areas and Geographic Regions
10.1.5 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
10.2 Social, Technological, Economic and Political (STEP) Analysis
10.2.1 Large and Ageing Population Eager to Buy Medicines
10.2.2 Shortcomings of Brazil’s Healthcare System
10.2.3 Government Aims for Greater Self-Sufficiency in Biotechnology and Health IT
10.2.4 Can Economic Growth Keep Pace with Healthcare Costs?
10.2.5 Political Environment Acts as Decisive Influence on the Market
10.2.6 Will BREXIT Affect Free Trade Negotiations with the EU?

11. Research Interviews
11.1 Interview With Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica
11.1.1 On Gaining Access to the Brazilian Market
11.1.2 Factors That Differentiate Brazil From Other Markets
11.1.3 The Brazilian Generics and Biosimilars Market and Biocad’s Progress with Biosimilars
11.1.4 Biocad’s Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future
11.1.5 Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East
11.1.6 Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market and How the 2016 Olympics Will Compare
11.1.7 Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses Will Improve in Coming Years
11.2 Interview with André Brazay, President of Sandoz Brazil
11.2.1 Impact of Current Political and Economic Situation
11.2.2 Challenges faced by Domestic Companies
11.2.3 How Generics Market in Brazil Differs from Other Countries
11.2.4 Importance of Biosimilars in Brazil
11.2.5 Factors for an Overseas Investor to Consider
11.2.6 Future Challenges for the Market in Brazil

12. Conclusions from Our Research and Analysis
12.1 Growth of Brazil’s Pharmaceutical Market Will Outstrip That of More Developed Countries
12.2 Generics Will be Major Driver of Growth
12.3 Technology Transfer Boosts Domestic Production of Originator Drugs
12.4 Generics Market Provides Alternative Option for Multinationals
12.5 Oncology is Leading Therapeutic and Commercial Opportunity
12.6 Concluding Comments

List of Tables
Table 1.1 Sample Table: Brazilian Pharmaceutical Market Breakdown
Table 1.2 Currency Exchange Rates: Average Historic Exchange Rate to USD for 2014 and 2015
Table 2.1 Brazilian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 2.2 Brazilian Pharmaceutical Market by Segment: Revenue ($bn) and Market Share (%), 2015
Table 2.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2015
Table 2.4 Brazilian Pharmaceutical Market: Top Ten Companies - Revenue ($bn) and Market Share (%), 2015
Table 3.1 World’s Largest Pharmaceutical Markets, Revenue ($bn) and Market Share (%), 2015
Table 3.2 Top Latin American Pharmaceutical Markets: Revenue ($bn) and Market Share (%), 2015
Table 3.3 Pharmerging Countries
Table 4.1 Members of FenaSaúde (in Portuguese, with English in Brackets), 2016
Table 6.1 Originator Drug, Generic Drug and OTC Drug Segments Forecast: Revenue ($bn) and Market Share (%), 2015-2026
Table 6.2 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2021
Table 6.3 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2026
Table 6.4 Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2015-2026
Table 6.5 Originator Drug Segment: Revenue Forecasts ($bn), 2015-2026
Table 6.6 Selected Technology Transfer Agreements in Brazil 1985-2013
Table 6.7 Generic Drug Segment: Revenue Forecasts ($bn), 2015-2026
Table 6.8 OTC Drug Segment: Revenue Forecasts ($bn), 2015-2026
Table 7.1 Brazilian Pharmaceutical Market – Therapeutic Areas: Revenue ($bn) and Market Share (%), 2015-2026
Table 7.2 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2021
Table 7.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2026
Table 7.4 CNS Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
Table 7.5 Cardiovascular Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
Table 7.6 Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
Table 7.7 Oncology Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
Table 7.8 Infectious Diseases Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
Table 7.9 Other Therapeutic Areas: Revenue ($bn) and Market Share (%), 2015-2026
Table 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenue ($bn) and Market Share (%), 2015
Table 8.2 EMS Overview
Table 8.3 Hypermarcas Overview
Table 8.4 Medley Overview
Table 8.5 Aché Overview
Table 8.6 Eurofarma Overview
Table 8.7 Teuto Overview
Table 8.8 Biolab Farmacêutica Overview
Table 8.9 Biolab Farmacêutica Pipeline, 2015
Table 8.10 Cristalia Overview
Table 8.11 Libbs Overview
Table 8.12 União Química Overview
Table 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2015
Table 9.2 Selected Multinational M&A Activity in the Brazilian Market, 2009-2012
Table 9.3 Sanofi Overview
Table 9.4 Novartis Overview
Table 9.5 Roche Overview
Table 9.6 Merck & Co. Overview
Table 9.7 Pfizer Overview
Table 9.8 Takeda Overview
Table 9.9 Bayer Overview
Table 9.10 AstraZeneca Overview
Table 9.11 Boehringer Ingelheim Overview
Table 9.12 Merck KGaA Overview
Table 10.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2016
Table 10.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2016
Table 10.3 Brazilian Pharmaceutical Market: STEP Analysis, 2016

List of Figures
Figure 1.1 Product Segments of Brazilian Pharmaceutical Market
Figure 1.2 Main Therapeutic Areas Within the Brazilian Pharmaceutical Market
Figure 2.1 Brazilian Pharmaceutical Market: Revenue ($bn) 2015-2026
Figure 2.2 Brazilian Pharmaceutical Market by Segment: Market Share (%), 2015
Figure 2.3 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2015
Figure 2.4 Brazilian Pharmaceutical Market: Top Ten Companies – Market Share (%), 2015
Figure 3.1 Top Ten Global Economies, 2015
Figure 3.2 Top Ten Global Economies, 2030
Figure 3.3 World’s Largest Pharmaceutical Markets by Market Share (%), 2015
Figure 3.4 Top Latin American Pharmaceutical Markets: Market Share (%), 2015
Figure 3.5 BRIC Countries Pharmaceutical Market Revenue ($bn), 2015
Figure 4.1 Public Healthcare Versus Private Healthcare: Market Share (%), 2015
Figure 5.1 Doctors per 1,000 Inhabitants by Brazilian Region, 2013
Figure 5.2 Brazil: Regional Population Shares (%), 2013
Figure 5.3 Brazilian Pharmaceutical Market Shares (%) by Region, 2012
Figure 5.4 Brazilian GDP Shares (%) by Region, 2013
Figure 6.1 Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2021
Figure 6.2 Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2026
Figure 6.3 Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2015-2026
Figure 6.4 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn), 2015, 2021, 2026
Figure 6.5 Originator Drug Segment: Revenue ($bn) 2015-2026
Figure 6.6 Drivers and Restraints for Patented Pharmaceuticals, 2016
Figure 6.7 Generic Drug Segment: Revenue ($bn) 2015-2026
Figure 6.8 Drivers and Restraints for Generic Drugs, 2016
Figure 6.9 Brazilian Biologics Market Breakdown: Revenue ($bn) and Market Share (%), 2015
Figure 6.10 Brazilian Biologics Market Breakdown: Revenue ($bn), 2015,2021, 2026
Figure 6.11 OTC Drug Segment: Revenue ($bn) 2015-2026
Figure 6.12 Drivers and Restraints for OTC Drugs, 2016
Figure 7.1 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2021
Figure 7.2 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2026
Figure 7.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue Forecasts ($bn), 2015-2026
Figure 7.4 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn), 2015, 2021, 2026
Figure 7.5 CNS Therapeutic Area: Revenue ($bn), 2015-2026
Figure 7.6 Drivers and Restraints for CNS Conditions, 2016
Figure 7.7 Cardiovascular Therapeutic Area: Revenue ($bn), 2015-2026
Figure 7.8 Drivers and Restraints for the Cardiovascular Therapy Area, 2016
Figure 7.9 Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn), 2015-2026
Figure 7.10 Drivers and Restraints for Gastrointestinal/Metabolic Therapy Area, 2016
Figure 7.11 Oncology Therapeutic Area: Revenue ($bn) 2015-2026
Figure 7.12 Estimated Cancer Incidence for Males in Brazil, 2016
Figure 7.13 Estimated Cancer Incidence for Females in Brazil, 2016
Figure 7.14 Drivers and Restraints for the Oncology Therapeutic Area, 2016
Figure 7.15 Infectious Diseases Therapeutic Area: Revenue ($bn), 2015-2026
Figure 7.16 Drivers and Restraints for the Infectious Disease Therapeutic Area, 2016
Figure 7.17 Other Therapeutic Areas: Revenue ($bn), 2015-2026
Figure 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Market Share (%), 2015
Figure 8.2 Aché Product Portfolio Breakdown (%), 2013
Figure 9.1 Leading Multinational Companies in the Brazilian Market: Market Shares (%), 2015
Figure 12.1 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2015-2021
Figure 12.2 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2021-2026
Figure 12.3 Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2015-2021
Figure 12.4 Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2021-2026
Figure 12.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenue ($bn), 2015
Figure 12.6 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2015-2021
Figure 12.7 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2021-2026



※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年10月23日現在 208,431 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。